241 related articles for article (PubMed ID: 38000306)
1. Loss of B1 and marginal zone B cells during ovarian cancer.
Maslanka J; Torres G; Londregan J; Goldman N; Silberman D; Somerville J; Riggs JE
Cell Immunol; 2024; 395-396():104788. PubMed ID: 38000306
[TBL] [Abstract][Full Text] [Related]
2. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice.
Hamaguchi Y; Uchida J; Cain DW; Venturi GM; Poe JC; Haas KM; Tedder TF
J Immunol; 2005 Apr; 174(7):4389-99. PubMed ID: 15778404
[TBL] [Abstract][Full Text] [Related]
3. A Novel Role for C5a in B-1 Cell Homeostasis.
Bröker K; Figge J; Magnusen AF; Manz RA; Köhl J; Karsten CM
Front Immunol; 2018; 9():258. PubMed ID: 29520270
[TBL] [Abstract][Full Text] [Related]
4. Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer.
Baert T; Vankerckhoven A; Riva M; Van Hoylandt A; Thirion G; Holger G; Mathivet T; Vergote I; Coosemans A
Front Immunol; 2019; 10():1273. PubMed ID: 31214202
[TBL] [Abstract][Full Text] [Related]
5. PPARγ activation modulates the balance of peritoneal macrophage populations to suppress ovarian tumor growth and tumor-induced immunosuppression.
Prat M; Coulson K; Blot C; Jacquemin G; Romano M; Renoud ML; AlaEddine M; Le Naour A; Authier H; Rahabi MC; Benmoussa K; Salon M; Parny M; Delord JP; Ferron G; Lefèvre L; Couderc B; Coste A
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586764
[TBL] [Abstract][Full Text] [Related]
6. The loss and gain of marginal zone and peritoneal B cells is different in response to relapsing fever and Lyme disease Borrelia.
Malkiel S; Kuhlow CJ; Mena P; Benach JL
J Immunol; 2009 Jan; 182(1):498-506. PubMed ID: 19109181
[TBL] [Abstract][Full Text] [Related]
7. Obesity modulates the cellular and molecular microenvironment in the peritoneal cavity: implication for ovarian cancer risk.
Shea AA; Heffron CL; Grieco JP; Roberts PC; Schmelz EM
Front Immunol; 2023; 14():1323399. PubMed ID: 38264656
[TBL] [Abstract][Full Text] [Related]
8. Intraperitoneal neutrophils activated by KRAS-induced ovarian cancer exert antitumor effects by modulating adaptive immunity.
Yoshida M; Taguchi A; Kawana K; Ogishima J; Adachi K; Kawata A; Nakamura H; Sato M; Fujimoto A; Inoue T; Tomio K; Mori M; Nagamatsu T; Arimoto T; Koga K; Hiraike OW; Oda K; Kiyono T; Osuga Y; Fujii T
Int J Oncol; 2018 Oct; 53(4):1580-1590. PubMed ID: 30066851
[TBL] [Abstract][Full Text] [Related]
9. Human B1 Cells are the Main Blood Group A-Specific B Cells That Have a Moderate Correlation With Anti-A Antibody Titer.
Xu Y; Lee JG; Yan JJ; Ryu JH; Xu S; Yang J
Ann Lab Med; 2020 Jan; 40(1):48-56. PubMed ID: 31432639
[TBL] [Abstract][Full Text] [Related]
10. Activation of B-1 Cells Promotes Tumor Cell Killing in the Peritoneal Cavity.
Haro MA; Dyevoich AM; Phipps JP; Haas KM
Cancer Res; 2019 Jan; 79(1):159-170. PubMed ID: 30224373
[TBL] [Abstract][Full Text] [Related]
11. A role for the nuclear receptor NR2F6 in peritoneal B cell homeostasis.
Olson WJ; Jakic B; Labi V; Woelk J; Derudder E; Baier G; Hermann-Kleiter N
Front Immunol; 2022; 13():845235. PubMed ID: 36052079
[TBL] [Abstract][Full Text] [Related]
12. NIM-R7, a novel marker for resting B1 and marginal-zone B lymphocytes, is also expressed on activated T and B cells.
Manjarrez-Orduño N; Parkhouse RM; Santos-Argumedo L
Immunology; 2003 Jun; 109(2):232-7. PubMed ID: 12757618
[TBL] [Abstract][Full Text] [Related]
13. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
[TBL] [Abstract][Full Text] [Related]
14. Murine B1 B cells require IL-5 for optimal T cell-dependent activation.
Erickson LD; Foy TM; Waldschmidt TJ
J Immunol; 2001 Feb; 166(3):1531-9. PubMed ID: 11160193
[TBL] [Abstract][Full Text] [Related]
15. Notch2 haploinsufficiency results in diminished B1 B cells and a severe reduction in marginal zone B cells.
Witt CM; Won WJ; Hurez V; Klug CA
J Immunol; 2003 Sep; 171(6):2783-8. PubMed ID: 12960298
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of peritoneal B-1a cells accumulation induced by murine lupus susceptibility locus Sle2.
Xu Z; Butfiloski EJ; Sobel ES; Morel L
J Immunol; 2004 Nov; 173(10):6050-8. PubMed ID: 15528340
[TBL] [Abstract][Full Text] [Related]
17. Microenvironmental effects limit efficacy of thymoquinone treatment in a mouse model of ovarian cancer.
Wilson AJ; Saskowski J; Barham W; Khabele D; Yull F
Mol Cancer; 2015 Nov; 14():192. PubMed ID: 26552746
[TBL] [Abstract][Full Text] [Related]
18. Exchange of macromolecules between plasma and peritoneal cavity in ascites tumor-bearing, normal, and serotonin-injected mice.
Nagy JA; Herzberg KT; Masse EM; Zientara GP; Dvorak HF
Cancer Res; 1989 Oct; 49(19):5448-58. PubMed ID: 2475250
[TBL] [Abstract][Full Text] [Related]
19. Carboplatin and programmed death-ligand 1 blockade synergistically produce a similar antitumor effect to carboplatin alone in murine ID8 ovarian cancer model.
Zhu X; Xu J; Cai H; Lang J
J Obstet Gynaecol Res; 2018 Feb; 44(2):303-311. PubMed ID: 29171115
[TBL] [Abstract][Full Text] [Related]
20. Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer.
Khan AN; Kolomeyevskaya N; Singel KL; Grimm MJ; Moysich KB; Daudi S; Grzankowski KS; Lele S; Ylagan L; Webster GA; Abrams SI; Odunsi K; Segal BH
Oncotarget; 2015 May; 6(13):11310-26. PubMed ID: 25888637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
